Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | CLK1 | P49759 | 5/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.44 |
| ▸ | CLK3 | P49761 | 3/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.44 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7 | P36402 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163509 | 1.00 | CYP2A6 (0.54) | CYP2A6MAOBCLK1DYRK1ACLK4 | |
| SCHEMBL2138250 | 0.86 | CYP2A6 (0.54) | CYP2A6MAOBESR1CCNCCDK8 | |
| SCHEMBL29570479 | 0.86 | CYP2A6 (0.54) | CYP2A6MAOBESR1CCNCCDK8 | |
| SCHEMBL18911976 | 0.82 | MAOB (0.52) | MAOBCLK1DYRK1ACLK4DYRK1B | |
| SCHEMBL23497966 | 0.79 | CYP2A6 (0.47) | CYP2A6MAOBMAOAPDE1C | |
| SCHEMBL30044048 | 0.79 | CYP2A6 (0.47) | CYP2A6MAOBMAOAPDE1C | |
| SCHEMBL28167573 | 0.79 | CYP2A6 (0.46) | CYP2A6MAOBALDH1A1RAB9A | |
| SCHEMBL13726686 | 0.79 | CYP2A6 (0.46) | CYP2A6MAOBCLK1DYRK1ACLK4 | |
| SCHEMBL3436601 | 0.78 | CYP2A6 (0.46) | CYP2A6MAOBALDH1A1 | |
| SCHEMBL27688161 | 0.78 | CYP2A6 (0.46) | CYP2A6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025040167-A1 | PHOSPHOINOSITIDE 3-KINASE ALLOSTERIC INHIBITOR FOR TREATING DISEASE RELATED TO PI3K REGULATION | 上海艾力斯医药科技股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-4499649-A1 | IKZF2 DEGRADERS AND USES THEREOF | Regents of the University of Michigan (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023183540-A1 | IKZF2 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-4073054-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885MAOB 225/4885CLK1 1650/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CYP2A6 3772/4885MAOB 3464/4885CLK1 1242/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CYP2A6 555/4885MAOB 165/4885CLK1 1569/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885MAOB 225/4885CLK1 1650/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CYP2A6 3772/4885MAOB 3464/4885CLK1 1242/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885MAOB 225/4885CLK1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.